{"id":"W2040200721","doi":"10.3851/imp1959","title":"Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Janssen Canada","keywords":"Rilpivirine; Efavirenz; Pharmacokinetics; Medicine; Pharmacology; Ex vivo; Internal medicine; In vivo; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001885935,0.0001487727,0.000384611,0.0001652684,0.00001766209,0.000002390621,0.00006404276,0.00004908557,0.00004266402],"category_scores_gemma":[0.00001107815,0.0001219065,0.0001249486,0.0002800073,0.00005352689,0.00008780703,0.000009271748,0.00008464765,0.000009546223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002884005,"about_ca_system_score_gemma":0.0001214556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009786394,"about_ca_topic_score_gemma":0.00002946234,"domain_scores_codex":[0.9989504,0.00006340445,0.0003993082,0.0001870222,0.0002007229,0.0001991477],"domain_scores_gemma":[0.9995835,0.00004539125,0.0001398355,0.0001562244,0.00002816909,0.0000468452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009206576,0.00240808,0.8010235,0.0001219736,0.0004368304,0.0002577838,0.005495278,5.8969e-7,0.0667819,0.0001098696,0.0001312621,0.1140263],"study_design_scores_gemma":[0.009986343,0.002510286,0.2980188,0.0002142529,0.00006540417,0.000007334907,0.0001794083,0.00005564859,0.6883715,0.0001031119,0.0003099059,0.0001780113],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961551,0.0003592171,0.00001811809,0.0002524728,0.0001044873,0.0004330074,0.000002718597,0.00001930799,0.00265554],"genre_scores_gemma":[0.9967201,0.0005881375,0.002150973,0.00009074601,0.00001497112,0.0000189853,0.00001797393,0.00001650502,0.0003815922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6215896,"threshold_uncertainty_score":0.4971202,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05700164969134133,"score_gpt":0.3226173704849523,"score_spread":0.265615720793611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}